Suárez López V J, Miñambres E, Robles Arista J C, Ballesteros M A
Servicio Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, España.
Med Intensiva. 2012 Oct;36(7):506-12. doi: 10.1016/j.medin.2012.03.017. Epub 2012 Jun 4.
Lung transplantation is a therapeutic option for pulmonary diseases in which the other treatment options have failed or in cases of rapid disease progression. However, transplantation is not free from complications, and primary graft dysfunction is one of them. Primary graft dysfunction is a form of acute lung injury. It characteristically develops during the immediate postoperative period, being associated to high morbidity and mortality, and increased risk of bronchiolitis obliterans. Different terms have been used in reference to primary graft dysfunction, leading to a consensus document to clarify the definition in 2005. This consensus document regards primary graft dysfunction as non-cardiogenic pulmonary edema developing within 72 hours of reperfusion and intrinsically attributable to alteration of the lung parenchyma. A number of studies have attempted to identify risk factors and to establish the underlying physiopathology, with a view to developing potential therapeutic options. Such options include nitric oxide and pulmonary surfactant together with supportive measures such as mechanical ventilation or oxygenation bypass.
肺移植是其他治疗方法失败或疾病快速进展情况下肺部疾病的一种治疗选择。然而,移植并非没有并发症,原发性移植功能障碍就是其中之一。原发性移植功能障碍是急性肺损伤的一种形式。其典型特征是在术后即刻发生,与高发病率和死亡率相关,且闭塞性细支气管炎的风险增加。关于原发性移植功能障碍使用了不同的术语,因此在2005年形成了一份共识文件来明确其定义。该共识文件将原发性移植功能障碍视为再灌注后72小时内发生的非心源性肺水肿,本质上归因于肺实质的改变。许多研究试图识别风险因素并确立潜在的病理生理学机制,以期开发出潜在的治疗方法。这些方法包括一氧化氮和肺表面活性物质,以及诸如机械通气或体外膜肺氧合等支持措施。